Skip to main content
. Author manuscript; available in PMC: 2022 Apr 7.
Published in final edited form as: Adv Exp Med Biol. 2021;1322:115–138. doi: 10.1007/978-981-16-0267-2_5

Table 5.9.

Nucleoside analog in development

Drug EC50 μM Route Company Clinical trial phase ClinicalTrials.gov identifier
ATI-2173 0.0013 Oral Antios Therapeutics, USA 1 NCT04248426

EC50 median effective concentration to inhibit HBV DNA replication